Advances in molecular targeted treatment for head and neck cancer
10.3760/cma.j.issn.1673-422X.2010.11.014
- VernacularTitle:头颈部癌的靶向治疗进展
- Author:
Yonghong HUA
- Publication Type:Journal Article
- Keywords:
Head and neck neoplasm;
Antibodies,monoclonal;
Receptor,epidermal growth factor
- From:
Journal of International Oncology
2010;37(11):845-848
- CountryChina
- Language:Chinese
-
Abstract:
Toxicity has impeded the advance of chemoradiotherapy for head and neck cancer, while targeted therapy has demonstrated some advantage. Over the past decade, targeted therapy is becoming the important section in multimodal approaches for head and neck cancer. Targeted drugs include monoclonal antibodies, small molecular chemicals and antisense oligodeoxynucleotide, etc. Cetuximab is the only targeted agent approved for this malignancy, and other targeted drugs, such as gefitinib and lapatinib, have demonstrated encouraging outcome in phase Ⅰ -Ⅲ clinical trials for head and neck cancer.
